Risk of Cardiovascular Disease Similar in Dual E-Cigarette and Traditional Cigarette Users: Study

May.09.2022
Risk of Cardiovascular Disease Similar in Dual E-Cigarette and Traditional Cigarette Users: Study
Using both traditional cigarettes and e-cigarettes may not lower cardiovascular disease risk and may have harmful health effects.

Key points of the research:

 

A study of over 24,000 American adults has found that using both traditional cigarettes and electronic cigarettes does not decrease the risk of cardiovascular disease and may lead to harmful health effects similar to smoking. Those who use both traditional cigarettes and e-cigarettes do not have significantly lower risks of heart attacks, heart failure, or strokes compared to those who only smoke, nor did they report any self-reported cardiovascular disease outcomes. While those who use only e-cigarettes reported fewer cardiovascular events than those who only smoked traditional cigarettes, the number of reported heart events was too small to draw clear conclusions on the effects of solely using e-cigarettes in the study sample. Researchers note the need for more long-term data on e-cigarette use. The study was published on May 6, 2022, in the flagship peer-reviewed journal "Circulation" of the American Heart Association.

 

Traditional cigarette smoking is widely recognized as a major cause of serious health conditions. According to updated statistics from the American Heart Association on heart disease and stroke in 2022, nearly one-fifth of all deaths in the United States each year are attributed to smoking and exposure to secondhand smoke. Electronic cigarettes, which contain numerous toxic chemicals, are increasingly popular as another way for people to consume nicotine.

 

According to Dr. Stokes, the lead investigator and senior author of the study, Andrew C. stated, "The risk of cardiovascular disease associated with dual use of traditional combustible cigarettes and electronic cigarettes, similar to smoking, is an important finding because many Americans are using e-cigarettes in an attempt to reduce smoking as they perceive the risk of e-cigarettes to be lower." Dr. Stokes, Assistant Professor in the Department of Global Health at the Boston University School of Public Health, further explained that "People are attempting to transition from traditional cigarettes to e-cigarettes, and dual use of both products is common.

 

To investigate the relationship between cardiovascular disease, the use of electronic and traditional cigarettes, and their combined use, researchers examined data from the Population Assessment of Tobacco and Health (PATH) study. This nationally representative study collected self-reported health and nicotine product usage information from over 24,000 adults between 2013 and 2019, across five annual waves. After adjusting for age, gender, and race/ethnicity, the study focused on adults, over 50% of whom were under the age of 35, and 51% of whom were female.

 

Participants who reported smoking during any round of data collection after smoking over 100 combustible cigarettes in their lifetime were classified as smokers. E-cigarette users were identified based on self-reported e-cigarette use during any round of data collection. The groups were classified as follows: 1) current non-users of e-cigarettes or combustible cigarettes (14,832 individuals; this group may include former smokers or former e-cigarette users); 2) e-cigarette use only (822 individuals); 3) combustible cigarette use only (6,515 individuals); or 4) mixed use of combustible cigarettes and e-cigarettes (1,858 individuals).

 

The analysis defined cardiovascular events as either self-reported diagnoses of a heart attack, coronary artery bypass surgery, heart failure, other heart conditions, or stroke within the past 12 months. The researchers also examined the specific outcomes of self-reported heart attack, heart failure, or stroke. The review identified over 1,480 cases of cardiovascular disease and more than 500 cases of heart attack, heart failure, or stroke.

 

Analysis of all study participants revealed:

 

Compared to those who only smoke traditional cigarettes, individuals who smoke both traditional cigarettes and use e-cigarettes do not have a significant difference in the risk of developing cardiovascular diseases such as heart attacks, heart failure, or strokes. Those who only use e-cigarettes or use both traditional and e-cigarettes are younger than those who do not use these products at all: 62% of e-cigarette only users and 54% of dual users are under the age of 35, compared to 51% of non-users. The researchers note that only using e-cigarettes has a reported 30%-40% lower risk of self-reported cardiovascular disease events compared to traditional smoking, although this association is important for any cardiovascular outcome, including congenital heart disease or myocarditis (e-cigarette users reported 41 events, compared to 569 for smokers), rather than specifically for heart attacks, heart failure, or strokes (15 events reported by e-cigarette users, compared to 242 for smokers). Considering the limited amount of self-reported data from e-cigarette users, the researchers conclude that more data is needed in this field.

 

Even though the PATH study is providing basic longitudinal data on traditional cigarette and e-cigarette use and cardiovascular events, the data is self-reported, the study duration is short, and the event rates are still low - especially among young people. As e-cigarette use is still relatively new, there is currently not a vast amount of long-term evidence to determine the ultimate risks associated with using these products over time. Therefore, we look forward to obtaining more data from this and other ongoing studies. It is important to remember that even with traditional cigarette use, it took decades of use and monitoring to provide us with the evidence we now have to confirm the significant harm of combustible cigarettes," said Rose Marie Robertson, MD, FAHA, American Heart Association deputy chief science and medical officer and co-director of the Tobacco Regulation and Addiction Center, which supports the study.

 

People should be aware that electronic cigarettes contain addictive nicotine and toxic chemicals that may have adverse effects on their cardiovascular system and overall health.

 

A key limitation noted by researchers in this study is the low incidence of individual and cardiovascular events in the group of exclusive e-cigarette users. While only 15 individuals who exclusively used e-cigarettes reported diagnoses of heart attack, heart failure, or stroke, the small number of individuals and events makes it difficult to draw definite conclusions about the impact of exclusive e-cigarette use on the study sample.

 

Stokes has stated that many smokers who attempt to quit using e-cigarettes actually continue to use both products, becoming dual users, and as a result, their cardiovascular risks do not decrease. "We are concerned that any recommendations for using e-cigarettes to quit smoking may lead to an increase in dual use among young people and never smokers, as well as initiation of e-cigarette use.

 

Electronic cigarettes are not approved by the US Food and Drug Administration (FDA) for smoking cessation. We urge anyone who smokes and is interested in quitting to discuss FDA-approved, effective smoking cessation options with their doctor and healthcare team," said Robertson.

 

The Tobacco Regulation Science Center of the American Heart Association received funding for this study through grants from the United States government. The Center for Tobacco Products at the Food and Drug Administration obtained the funding through the National Heart, Lung, and Blood Institute at the National Institutes of Health. The American Heart Association is working closely with investigators from institutions across the nation through this Center to conduct research aimed at increasing existing knowledge about the health effects of smoking and nicotine-containing products (including e-cigarettes). These findings can help provide information for public health and tobacco product regulation.

 

The co-authors of this work are Jonathan B. Bellows, B.A.; Wubin Xie, Dr.P.H., M.P.H.; Alyssa F. Halbower, Dr.P.H., M.P.H.; Naomi M. Hamburg, M.D.; Michael J. Blaha, M.D., M.P.H.; Aruni Bhatnagar, Ph.D., FAHA; and Emelia J. Benjamin, M.D., Sc.M., FAHA.

 

Source: American Heart Association.

 


Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Product | PMI Launches TEREA Black Mint Pearl in Japan, Adding First Capsule Variant to Black Range With Nationwide Rollout From October 19
Philip Morris Japan (PMJ) launched TEREA Black Mint Pearl on October 15, 2026, introducing the first capsule-equipped heated tobacco stick in the TEREA Black range for IQOS ILUMA devices. The product combines a strong menthol profile with a crushable mint capsule and is priced at ¥640 per 20-stick pack, including tax. Sales began at four IQOS stores and selected retail partners on October 15, with distribution expanding to convenience stores and other tobacco retailers nationwide from October 19. The launch brings Japan's TEREA portfolio to 28 variants, including 21 menthol-related products, or 75% of the range.
product
Oct.16 by 2Firsts Perspectives
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China Tobacco Plans CNY 60 Billion Investment in ICBC, Agricultural Bank as Strategic Ties Extend Beyond Equity
China National Tobacco Corporation and several subsidiaries plan to invest a combined CNY 60 billion ($8.7 billion) in share placements by Industrial and Commercial Bank of China and Agricultural Bank of China as strategic investors. The agreements extend beyond equity investment to corporate governance, banking services and supply-chain finance. The filings also disclose 2025 data on China Tobacco’s tax and profit contributions and industry scale.
Sep.07
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
Juul Sublicense Reshapes Vuse Alto Patent Bill as Court Ends R.J. Reynolds’ 5.25% Royalty Obligation to Altria
According to Law360 on August 31, 2026, a federal judge in North Carolina ruled that a patent sublicense between R.J. Reynolds Vapor Co. and Juul Labs Inc. relieves Reynolds of its obligation to continue paying royalties to Altria Client Services LLC over Vuse Alto. A jury had previously found that Vuse Alto infringed three Altria patents and awarded approximately $95.2 million in past damages, after which Reynolds was ordered to pay an ongoing royalty equal to 5.25% of positive net sales. The new ruling finds that a valid sublicense can eliminate future infringement, potentially ending what Altria described as hundreds of millions of dollars in future royalties.
Sep.01
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
UK HMRC Launches Vape Duty Stamps on October 1, Ushering in Supply-Chain Traceability as Chinese Exporters Face New Compliance Hurdles
HM Revenue & Customs put the UK's Vaping Products Duty and Vaping Duty Stamps Scheme into effect on October 1. All vaping liquids manufactured in or imported into the UK are now subject to duty at £2.20 per 10ml, regardless of nicotine content. The stamp regime will introduce digital functionality designed to provide traceability throughout the supply chain, with approved manufacturers, importers and warehousekeepers required to report product movements and retailers and consumers eventually able to scan stamps to verify authenticity. China exported $177 million of vape-related products to the UK in August, up 51.4% year over year, increasing the significance of the new compliance regime for China's Shenzhen-centered vape supply chain.
Regulations
Oct.04
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Q4 Revenue Rebounds 33% but Full-Year Sales Still Fall 25% as FY2027 Focus Shifts to Malaysia Manufacturing, ODM, Nicotine Pouches and Age Verification
Ispire Technology reported FY2026 revenue of about $96 million, down 24.7% year over year, as U.S. cannabis-vapor hardware and European e-cigarette sales declined by $17.4 million and $12.7 million, respectively. Fourth-quarter revenue rose 32.5% to $26.7 million, while quarterly gross margin fell to 6.3%. For FY2027, the company is prioritizing Malaysia manufacturing and vapor ODM while continuing to develop nicotine pouches, IKE Tech age-verification technology and G-Mesh licensing. Ispire has not separately disclosed the revenue or profit contribution of those newer businesses.
Regulations
Sep.17 by 2Firsts Perspectives